Modality
siRNA
MOA
CAR-T CD19
Target
GLP-1R
Pathway
Tau
MMHCCThymoma
Development Pipeline
Preclinical
~Oct 2020
→ ~Jan 2022
Phase 1
Apr 2022
→ Jul 2025
Phase 1Current
NCT08445518
2,273 pts·Thymoma
2022-04→2025-07·Terminated
2,273 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-07-178mo agoPh2 Data· Thymoma
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3
P1/2
Termina…
Catalysts
Ph2 Data
2025-07-17 · 8mo ago
Thymoma
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08445518 | Phase 1/2 | Thymoma | Terminated | 2273 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| Tirzepatide | Eli Lilly | Approved | GLP-1R | |
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Datoglumide | AbbVie | Approved | CFTR | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| Mavuglumide | Bayer | Approved | GLP-1R | |
| Bemarelsin | Daiichi Sankyo | Preclinical | GLP-1R |